Earnings call transcript: Charles River Labs Q2 2025 beats EPS forecasts

Charles River Laboratories (CRL) reported Q2 2025 EPS of $3.12 and revenue of $1.03 billion, significantly exceeding analyst expectations. Despite this strong earnings beat, the stock declined 10.57% pre-market, reflecting investor apprehension over a projected 1-3% full-year organic revenue decline and broader market conditions. The company raised its full-year EPS guidance to $9.90-$10.30, citing stabilizing demand in its Discovery and Safety Assessment (DSA) segment, ongoing cost savings, and the positive resolution of a DOJ investigation into NHP shipments, which enhances supply flexibility.

Analysis

Charles River Laboratories (CRL) presented a dichotomous second-quarter 2025 report, characterized by a significant earnings beat but a cautious forward outlook that triggered a negative market reaction. The company posted an EPS of $3.12, decisively surpassing the $2.50 consensus forecast by 24.8%, and revenue of $1.03 billion, which also exceeded expectations. Despite this demonstrated operational outperformance, driven by strong execution in the Discovery and Safety Assessment (DSA) segment, the stock declined 10.57% pre-market. This response appears linked to the company's guidance for a full-year organic revenue decline of 1% to 3%, signaling that near-term growth challenges persist. The DSA segment's net book-to-bill ratio, a key forward-looking metric, dipped to 0.82x in Q2, reinforcing the non-linear nature of the demand recovery, even as management noted a stabilizing environment, particularly among large pharma clients.

Contrasting the headwinds, several positive developments provide a more nuanced picture. Management raised its full-year EPS guidance to a range of $9.90 to $10.30, reflecting confidence underpinned by over $175 million in expected cost savings for 2025 and active share repurchases. Critically, the company announced the conclusion of the DOJ investigation into its Cambodian NHP shipments, a significant de-risking event that removes a major regulatory overhang and enhances supply chain flexibility. However, investors must balance these positives against specific second-half headwinds, including the loss of a commercial CDMO client relationship that contributed approximately $20 million in first-half revenue, a $10 million cost increase from renewed hiring in the DSA segment, and an anticipated rise in the effective tax rate.

Key Decisions for Investors

• Investors should weigh the current valuation, post-10.57% price decline, against the company's raised full-year EPS guidance, as the negative market reaction to the organic revenue forecast may present a dislocation for long-term holders.
• Closely monitor the Discovery and Safety Assessment (DSA) segment's net book-to-bill ratio in subsequent quarters; while management has guided for a sub-1.0 ratio, any sustained improvement towards or above 1.0 would be a strong leading indicator of a return to organic growth.
• Factor in the significant de-risking from the conclusion of the DOJ's NHP investigation, as this removes a key uncertainty and improves operational flexibility, which may not be fully reflected in the current stock price.
• Anticipate near-term margin pressure in the second half of 2025 due to the confirmed loss of a CDMO client, increased staffing costs, and a higher tax rate, which are expected to moderate profitability compared to the first half's outperformance.